Compare FIEE & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIEE | SCLX |
|---|---|---|
| Founded | 1977 | 2011 |
| Country | Hong Kong | United States |
| Employees | 30 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 35.2M |
| IPO Year | 2010 | 2020 |
| Metric | FIEE | SCLX |
|---|---|---|
| Price | $3.88 | $4.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.2K | ★ 28.1K |
| Earning Date | 05-14-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.46 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $47,988,549.00 | $30,253,000.00 |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | $22.24 | ★ N/A |
| Revenue Growth | ★ 27.58 | N/A |
| 52 Week Low | $1.50 | $4.20 |
| 52 Week High | $10.59 | $29.84 |
| Indicator | FIEE | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 36.39 |
| Support Level | $3.74 | $4.85 |
| Resistance Level | $3.97 | $5.60 |
| Average True Range (ATR) | 0.20 | 0.31 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 30.00 | 11.69 |
FiEE Inc is a digital service provider focused on integrating artificial intelligence (AI) and data analytics into content creation, digital authentication, and brand management. Its business model leverages a cloud-based SaaS platform designed to support clients in developing, managing, and optimizing their digital presence across platforms, including customized graphics and posts, short videos, and editorial calendars aligned with brand goals. Additionally, it offers comprehensive software development and maintenance services, delivering custom software solutions from system design and development to deployment and post-launch maintenance. It services consist of three core areas: digital content and MCN services, software development services, and digital authentication services.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.